Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: Dapagliflozin; Metformin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• 20 ≤ Age < 80 years

• HbA1c ≥ 7 %

• combination therapy with glimepiride and metformin over 2 months.

• dosage of glimepiride : 1-8mg/day

• dosage of metformin : 500-2550mg/day

Exclusion Criteria:

• Type 1 diabetes, gestational diabetes, or secondary forms of diabetes

• Contraindication to sitagliptin or dapagliflozin or lobeglitazone

• Pregnant or breast feeding women

• Medication which affect glycemic control (ex. steroid)

• Disease which affect efficacy and safety of drugs

• Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)

• Not appropriate for oral antidiabetic agent